Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Treatment Options in Oncology
Published in: Current Treatment Options in Oncology 4/2024

Open Access 13-03-2024 | Breast Cancer

Ovarian Suppression: Early Menopause and Late Effects

Authors: Chiara Molinelli, MD, Flavia Jacobs, MD, Guilherme Nader-Marta, MD, Roberto Borea, MD, Graziana Scavone, MSc, Silvia Ottonello, MSc, Piero Fregatti, MD, PhD, Cynthia Villarreal-Garza, MD, PhD, Jyoti Bajpai, MD, Hee Jeong Kim, MD, PhD, Silvia Puglisi, MD, Evandro de Azambuja, MD, PhD, Matteo Lambertini, MD, PhD

Published in: Current Treatment Options in Oncology | Issue 4/2024

Login to get access

Opinion statement

Around 90% of breast tumours are diagnosed in the early stage, with approximately 70% being hormone receptor-positive. The cornerstone of adjuvant therapy for early-stage hormone receptor-positive breast cancer is endocrine therapy, tailored according to disease stage, biological characteristics of the tumour, patient’s comorbidities, preferences and age. In premenopausal patients with hormone receptor-positive breast cancer, ovarian function suppression is a key component of the adjuvant endocrine treatment in combination with an aromatase inhibitor or tamoxifen. Moreover, it can be used during chemotherapy as a standard strategy for ovarian function preservation in all breast cancer subtypes. In the metastatic setting, ovarian function suppression should be used in all premenopausal patients with hormone receptor-positive breast cancer to achieve a post-menopausal status. Despite its efficacy, ovarian function suppression may lead to several side effects that can have a major negative impact on patients’ quality of life if not properly managed (e.g. hot flashes, depression, cognitive impairment, osteoporosis, sexual dysfunction, weight gain). A deep knowledge of the side effects of ovarian function suppression is necessary for clinicians. A correct counselling in this regard and proactive management should be considered a fundamental part of survivorship care to improve treatment adherence and patients’ quality of life.
Literature
1.
Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A, et al. Breast cancer statistics, 2022. CA Cancer J Clin. 2022;72(6):524–41.PubMedCrossRef
2.
Partridge AH, Hughes ME, Warner ET, Ottesen RA, Wong YN, Edge SB, et al. Subtype-dependent relationship between young age at diagnosis and breast cancer survival. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34(27):3308–14.CrossRef
3.
Kim HJ, Kim S, Freedman RA, Partridge AH. The impact of young age at diagnosis (age <40 years) on prognosis varies by breast cancer subtype: A U.S. SEER database analysis. The Breast. 2022;61:77–83.PubMedCrossRef
4.
Sparano JA, Gray RJ, Ravdin PM, Makower DF, Pritchard KI, Albain KS, et al. Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. N Engl J Med. 2019;380(25):2395–405.PubMedPubMedCentralCrossRef
5.
Lambertini M, Peccatori FA, Demeestere I, Amant F, Wyns C, Stukenborg JB, et al. Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines†. Ann Oncol. 2020;31(12):1664–78.PubMedCrossRef
6.
Lambertini M, Moore HCF, Leonard RCF, Loibl S, Munster P, Bruzzone M, et al. Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: a systematic review and meta-analysis of individual patient-level data. J Clin Oncol. 2018;36(19):1981–90.PubMedPubMedCentralCrossRef
7.
Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(8):1194–220.PubMedCrossRef
8.
Patterson-Lomba O, Dalal AA, Ayyagari R, Liu O, Dervishi E, Platt E, et al. Systematic literature review of clinical trials of endocrine therapies for premenopausal women with metastatic HR+ HER2- breast cancer. Breast J. 2019;25(5):880–8.PubMedCrossRef
9.
Li M, Huang H, Liang Y, Tan J, Lin D. Effect of Zoladex administered before chemotherapy on menstruation of patients with breast cancer. Chin J Clin Oncol. 2008;35:905–7.
10.
Sverrisdottir A, Nystedt M, Johansson H, Fornander T. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. Breast Cancer Res Treat. 2009;117(3):561–7.PubMedCrossRef
11.
Badawy A, Elnashar A, El-Ashry M, Shahat M. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril. 2009;91(3):694–7.PubMedCrossRef
12.
Gerber B, von Minckwitz G, Stehle H, Reimer T, Felberbaum R, Maass N, et al. Effect of luteinizing hormone–releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol. 2011;29(17):2334–41.PubMedCrossRef
13.
Sun J, Ren Y, Li W. Effect of Zoladex Administered before Chemotherapy on Menstruation of Patients with Breast Cancer. Chin Disab Med. 2011;19:15–6.
14.
Munster PN, Moore AP, Ismail-Khan R, Cox CE, Lacevic M, Gross-King M, et al. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol. 2012;30(5):533–8.PubMedPubMedCentralCrossRef
15.
Elgindy EA, El-Haieg DO, Khorshid OM, Ismail EI, Abdelgawad M, Sallam HN, et al. Gonadatrophin suppression to prevent chemotherapy-induced ovarian damage: a randomized controlled trial. Obstet Gynecol. 2013;121(1):78–86.PubMedCrossRef
16.
Song G, Gao H, Yuan Z. Effect of leuprolide acetate on ovarian function after cyclophosphamide–doxorubicin-based chemotherapy in premenopausal patients with breast cancer: results from a phase II randomized trial. Med Oncol. 2013;30(3):667.PubMedCrossRef
17.
Jiang FY, Zhang QQ, Zeng J. Protective effect of GnRHa on chemotherapy induced ovarian damage in breast cancer patients. Shandong Med J. 2013;53:16–8.
18.
Karimi-Zarchi M, Forat-Yazdi M, Vafaeenasab MR, Nakhaie-Moghadam M, Miratashi-Yazdi A, Teimoori S, et al. Evaluation of the effect of GnRH agonist on menstrual reverse in breast cancer cases treated with cyclophosphamide. Eur J Gynaecol Oncol. 2014;35(1):59–61.PubMed
19.
Moore HCF, Unger JM, Phillips KA, Boyle F, Hitre E, Moseley A, et al. Final analysis of the prevention of early menopause study (POEMS)/SWOG Intergroup S0230. JNCI J Natl Cancer Inst. 2019;111(2):210–3.PubMedCrossRef
20.
Lambertini M, Boni L, Michelotti A, Gamucci T, Scotto T, Gori S, et al. Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival: a randomized clinical trial. JAMA. 2015;314(24):2632.PubMedCrossRef
21.
Leonard RCF, Adamson DJA, Bertelli G, Mansi J, Yellowlees A, Dunlop J, et al. GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial. Ann Oncol. 2017;28(8):1811–6.PubMedCrossRef
22.
Zhang Y, Ji Y, Li J, Lei L, Wu S, Zuo W, et al. Sequential versus simultaneous use of chemotherapy and gonadotropin-releasing hormone agonist (GnRHa) among estrogen receptor (ER)-positive premenopausal breast cancer patients: effects on ovarian function, disease-free survival, and overall survival. Breast Cancer Res Treat. 2018;168(3):679–86.PubMedCrossRef
23.
Zong X, Yu Y, Yang H, Chen W, Ding X, Liu S, et al. Effects of gonadotropin-releasing hormone analogs on ovarian function against chemotherapy-induced gonadotoxic effects in premenopausal women with breast cancer in China: a randomized clinical trial. JAMA Oncol. 2022;8(2):252.PubMedCrossRef
24.
Lambertini M, Horicks F, Del Mastro L, Partridge AH, Demeestere I. Ovarian protection with gonadotropin-releasing hormone agonists during chemotherapy in cancer patients: from biological evidence to clinical application. Cancer Treat Rev. 2019;72:65–77.PubMedCrossRef
25.
Del Mastro L, Boni L, Michelotti A, Gamucci T, Olmeo N, Gori S, et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA. 2011;306(3):269–76.PubMed
26.
Lambertini M, Boni L, Michelotti A, Magnolfi E, Cogoni AA, Mosconi AM, et al. Long-term outcomes with pharmacological ovarian suppression during chemotherapy in premenopausal early breast cancer patients. JNCI J Natl Cancer Inst. 2022;114(3):400–8.PubMedCrossRef
27.
Li ZY, Dong YL, Cao XZ, Ren SS, Zhang Z. Gonadotropin-releasing hormone agonists for ovarian protection during breast cancer chemotherapy: a systematic review and meta-analysis. Menopause N Y N. 2022;29(9):1093–100.CrossRef
28.
Yang B, Shi W, Yang J, Liu H, Zhao H, Li X, et al. Concurrent treatment with gonadotropin-releasing hormone agonists for chemotherapy-induced ovarian damage in premenopausal women with breast cancer: a meta-analysis of randomized controlled trials. The Breast. 2013;22(2):150–7.PubMedCrossRef
29.
Wang C, Chen M, Fu F, Huang M. Gonadotropin-releasing hormone analog cotreatment for the preservation of ovarian function during gonadotoxic chemotherapy for breast cancer: a meta-analysis. PLoS ONE. 2013;8(6): e66360.PubMedPubMedCentralCrossRef
30.
Vitek WS, Shayne M, Hoeger K, Han Y, Messing S, Fung C. Gonadotropin-releasing hormone agonists for the preservation of ovarian function among women with breast cancer who did not use tamoxifen after chemotherapy: a systematic review and meta-analysis. Fertil Steril. 2014;102(3):808-815.e1.PubMedCrossRef
31.
Shen Y, Fujii T, Ueno NT, Tripathy D, Fu N, Zhou H, et al. Comparative efficacy of adjuvant trastuzumab-containing chemotherapies for patients with early HER2-positive primary breast cancer: a network meta-analysis. Breast Cancer Res Treat. 2019;173(1):1–9.PubMedCrossRef
32.
Lambertini M, Ceppi M, Poggio F, Peccatori FA, Azim HA, Ugolini D, et al. Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. Ann Oncol. 2015;26(12):2408–19.PubMedCrossRef
33.
Munhoz RR, Pereira AAL, Sasse AD, Hoff PM, Traina TA, Hudis CA, et al. Gonadotropin-releasing hormone agonists for ovarian function preservation in premenopausal women undergoing chemotherapy for early-stage breast cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;2(1):65.PubMedPubMedCentralCrossRef
34.
Silva C, Caramelo O, Almeida-Santos T, Ribeiro Rama AC. Factors associated with ovarian function recovery after chemotherapy for breast cancer: a systematic review and meta-analysis. Hum Reprod. 2016;31(12):2737–49.PubMedCrossRef
35.
Bai F, Lu Y, Wu K, Chen Q, Ding L, Ge M, et al. Protecting effects of gonadotropin-releasing hormone agonist on chemotherapy-induced ovarian damage in premenopausal breast cancer patients: a systematic review and meta-analysis. Breast Care Basel Switz. 2017;12(1):48–52.
36.
The ESHRE Guideline Group on Female Fertility Preservation, Anderson RA, Amant F, Braat D, D’Angelo A, de Sousa Chuva, Lopes SM, et al. ESHRE guideline: female fertility preservation†. Hum Reprod Open. 2020;2020(4):hoaa052.PubMedCentralCrossRef
37.
Oktay K, Harvey BE, Partridge AH, Quinn GP, Reinecke J, Taylor HS, et al. Fertility preservation in patients with cancer: ASCO Clinical Practice Guideline update. J Clin Oncol. 2018;36(19):1994–2001.PubMedCrossRef
38.
Lambertini M, Cinquini M, Moschetti I, Peccatori FA, Anserini P, ValenzanoMenada M, et al. Temporary ovarian suppression during chemotherapy to preserve ovarian function and fertility in breast cancer patients: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology. Eur J Cancer. 2017;1990(71):25–33.CrossRef
39.
Kim SE, Kim WJ, Choi D, Lee DY. Comparison of goserelin and leuprorelin for ovarian protection during chemotherapy in young patients with breast cancer. Breast Cancer Res Treat. 2023;198(2):231–7.PubMedCrossRef
40.
Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KA, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO Clinical Practice Guideline focused update. J Clin Oncol. 2019;37(5):423–38.PubMedCrossRef
41.
Paluch-Shimon S, Cardoso F, Partridge AH, Abulkhair O, Azim HA, Bianchi-Micheli G, et al. ESO-ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4). Ann Oncol. 2020;31(6):674–96.PubMedCrossRef
42.
Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019;30(8):1194–220.PubMedCrossRef
43.
Heer E, Harper A, Escandor N, Sung H, McCormack V, Fidler-Benaoudia MM. Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study. Lancet Glob Health. 2020;8(8):e1027–37.PubMedCrossRef
44.
Freedman RA, Partridge AH. Emerging data and current challenges for young, old, obese, or male patients with breast cancer. Clin Cancer Res. 2017;23(11):2647–54.PubMedCrossRef
45.
Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M, et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015;372(5):436–46.PubMedCrossRef
46.
Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Láng I, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med. 2018;379(2):122–37.PubMedPubMedCentralCrossRef
47.
Francis PA, Fleming GF, Láng I, Ciruelos EM, Bonnefoi HR, Bellet M, et al. Adjuvant endocrine therapy in premenopausal breast cancer: 12-year results from SOFT. J Clin Oncol. 2023;41(7):1370–5.PubMedCrossRef
48.
Pagani O, Walley BA, Fleming GF, Colleoni M, Láng I, Gomez HL, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer: long-term follow-up of the combined TEXT and SOFT trials. J Clin Oncol. 2023;41(7):1376–82.PubMedCrossRef
49.
Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Knauer M, Moik M, et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Ann Oncol. 2015;26(2):313–20.PubMedCrossRef
50.
Perrone F, De Laurentiis M, De Placido S, Orditura M, Cinieri S, Riccardi F, et al. Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial. Eur J Cancer. 2019;1990(118):178–86.CrossRef
51.
Kim HA, Lee JW, Nam SJ, Park BW, Im SA, Lee ES, et al. Adding ovarian suppression to tamoxifen for premenopausal breast cancer: a randomized phase III trial. J Clin Oncol. 2020;38(5):434–43.PubMedCrossRef
52.
Tevaarwerk AJ, Wang M, Zhao F, Fetting JH, Cella D, Wagner LI, et al. Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2014;32(35):3948–58.PubMedPubMedCentralCrossRef
53.
Baek SY, Noh WC, Ahn SH, Kim HA, Ryu JM, Kim SI, et al. Adding ovarian suppression to tamoxifen for premenopausal women with hormone receptor-positive breast cancer after chemotherapy: an 8-year follow-up of the ASTRRA trial. J Clin Oncol. 2023;41(31):4864–71.PubMedCrossRef
54.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. Lancet Oncol. 2022;23(3):382–92.CrossRef
55.
Pagani O, Francis PA, Fleming GF, Walley BA, Viale G, Colleoni M, et al. Absolute improvements in freedom from distant recurrence to tailor adjuvant endocrine therapies for premenopausal women: results from TEXT and SOFT. J Clin Oncol. 2020;38(12):1293–303.PubMedCrossRef
56.
Lambertini M, Blondeaux E, Perrone F, Del Mastro L. Improving adjuvant endocrine treatment tailoring in premenopausal women with hormone receptor–positive breast cancer. J Clin Oncol. 2020;38(12):1258–67.PubMedCrossRef
57.
Regan MM, Francis PA, Pagani O, Fleming GF, Walley BA, Viale G, et al. Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: TEXT and SOFT trials. J Clin Oncol. 2016;34(19):2221–31.PubMedPubMedCentralCrossRef
58.
Saha P, Regan MM, Pagani O, Francis PA, Walley BA, Ribi K, et al. Treatment efficacy, adherence, and quality of life among women younger than 35 years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant endocrine therapy trials. J Clin Oncol. 2017;35(27):3113–22.PubMedPubMedCentralCrossRef
59.
Jacobs F, Gaudio M, Benvenuti C, De Sanctis R, Santoro A, Zambelli A. Controversies and opportunities in the clinical daily use of the 21-gene assay for prognostication and prediction of chemotherapy benefit in HR+/HER2- early breast cancer. Cancers. 2022;15(1):148.PubMedPubMedCentralCrossRef
60.
Andre F, Ismaila N, Allison KH, Barlow WE, Collyar DE, Damodaran S, et al. Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update. J Clin Oncol. 2022;40(16):1816–37.PubMedCrossRef
61.
Villarreal-Garza C, Ferrigno AS, De la Garza-Ramos C, Barragan-Carrillo R, Lambertini M, Azim HA. Clinical utility of genomic signatures in young breast cancer patients: a systematic review. NPJ Breast Cancer. 2020;6:46.PubMedPubMedCentralCrossRef
62.
Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379(2):111–21.PubMedPubMedCentralCrossRef
63.
Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, et al. 21-Gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 2021;385(25):2336–47.PubMedPubMedCentralCrossRef
64.
Harbeck N, Gluz O, Christgen M, Graeser M, Hilpert F, Krauss K, et al. ADAPTcycle: Adjuvant dynamic marker-adjusted personalized therapy (ADAPT) comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk HR+/HER2- early breast cancer (EBC). J Clin Oncol. 2020;38(15_suppl):TPS601–TPS601.CrossRef
65.
Gluz O, Nitz UA, Christgen M, Kuemmel S, Braun M, Thill M, et al. LBA14 Impact of age, recurrence score (RS) and ovarian function suppression (OFS) on endocrine response to short preoperative endocrine therapy (ET): analysis of ADAPT and ADAPTcycle trials. Ann Oncol. 2022;1(33):S1382–3.CrossRef
66.
Nitz UA, Gluz O, Kümmel S, Christgen M, Braun M, Aktas B, et al. Endocrine therapy response and 21-gene expression assay for therapy guidance in HR+/HER2– early breast cancer. J Clin Oncol. 2022;40(23):2557–67.PubMedCrossRef
67.
Bernhard J, Luo W, Ribi K, Colleoni M, Burstein HJ, Tondini C, et al. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. Lancet Oncol. 2015;16(7):848–58.PubMedPubMedCentralCrossRef
68.
Lambertini M, Arecco L, Woodard TL, Messelt A, Rojas KE. Advances in the management of menopausal symptoms, fertility preservation, and bone health for women with breast cancer on endocrine therapy. Am Soc Clin Oncol Educ Book. 2023;43: e390442.PubMedCrossRef
69.
Leon-Ferre RA, Majithia N, Loprinzi CL. Management of hot flashes in women with breast cancer receiving ovarian function suppression. Cancer Treat Rev. 2017;52:82–90.PubMedCrossRef
70.
Freedman RR. Hot flashes: behavioral treatments, mechanisms, and relation to sleep. Am J Med. 2005;118(12):124–30.PubMedCrossRef
71.
Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. JNCI J Natl Cancer Inst. 1998;90(18):1371–88.PubMedCrossRef
72.
Bordeleau L, Pritchard KI, Loprinzi CL, Ennis M, Jugovic O, Warr D, et al. Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors. J Clin Oncol. 2010;28(35):5147–52.PubMedCrossRef
73.
74.
Stearns V, Beebe KL, Iyengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA. 2003;289(21):2827.PubMedCrossRef
75.
Gordon PR, Kerwin JP, Boesen KG, Senf J. Sertraline to treat hot flashes: a randomized controlled, double-blind, crossover trial in a general population. Menopause. 2006;13(4):568–75.PubMedCrossRef
76.
Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst. 2003;95(23):1758–64.PubMedCrossRef
77.
78.
Franzoi MA, Agostinetto E, Perachino M, Del Mastro L, de Azambuja E, Vaz-Luis I, et al. Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer. Lancet Oncol. 2021;22(7):e303–13.PubMedCrossRef
79.
Mols F, Husson O, Roukema JA, van de Poll-Franse LV. Depressive symptoms are a risk factor for all-cause mortality: results from a prospective population-based study among 3,080 cancer survivors from the PROFILES registry. J Cancer Surviv Res Pract. 2013;7(3):484–92.CrossRef
80.
Charles C, Bardet A, Larive A, Gorwood P, Ramoz N, Thomas E, et al. Characterization of depressive symptoms trajectories after breast cancer diagnosis in women in France. JAMA Netw Open. 2022;5(4): e225118.PubMedPubMedCentralCrossRef
81.
Jiang J, Xu J, Cai L, Man L, Niu L, Hu J, et al. Major depressive symptoms in breast cancer patients with ovarian function suppression: a cross-sectional study comparing ovarian ablation and gonadotropin-releasing hormone agonists. BMC Psychiatry. 2021;21(1):624.PubMedPubMedCentralCrossRef
82.
Mitchell AJ, Ferguson DW, Gill J, Paul J, Symonds P. Depression and anxiety in long-term cancer survivors compared with spouses and healthy controls: a systematic review and meta-analysis. Lancet Oncol. 2013;14(8):721–32.PubMedCrossRef
83.
Yi H, Nam S, Kim S, Lee J, Lee S, Bae S, et al. Abstract P1–11–01: depression and anxiety after adjuvant ovarian function suppression in premenopausal breast cancer patients. Cancer Res. 2016;76(4_Supplement):P1-11–01.CrossRef
84.
Lan B, Jiang SY, Li T, Ma F. The effect of ovarian function suppression on the psychological status of breast cancer patients under 35 years old in China. Zhonghua Zhong Liu Za Zhi. 2020;42(7):586–9.PubMed
85.
Williams S, Dale J. The effectiveness of treatment for depression/depressive symptoms in adults with cancer: a systematic review. Br J Cancer. 2006;94(3):372–90.PubMedPubMedCentralCrossRef
86.
87.
Bender CM, Sereika SM, Brufsky AM, Ryan CM, Vogel VG, Rastogi P, et al. Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer. Menopause N Y N. 2007;14(6):995–8.CrossRef
88.
Janelsins MC, Heckler CE, Peppone LJ, Kamen C, Mustian KM, Mohile SG, et al. Cognitive complaints in survivors of breast cancer after chemotherapy compared with age-matched controls: an analysis from a nationwide, multicenter, prospective longitudinal study. J Clin Oncol. 2017;35(5):506–14.PubMedCrossRef
89.
Garcia-Segura LM. Aromatase in the brain: not just for reproduction anymore. J Neuroendocrinol. 2008;20(6):705–12.PubMedCrossRef
90.
Boele FW, Schilder CMT, de Roode ML, Deijen JB, Schagen SB. Cognitive functioning during long-term tamoxifen treatment in postmenopausal women with breast cancer. Menopause N Y N. 2015;22(1):17–25.CrossRef
91.
Phillips KA, Regan MM, Ribi K, Francis PA, Puglisi F, Bellet M, et al. Adjuvant ovarian function suppression and cognitive function in women with breast cancer. Br J Cancer. 2016;114(9):956–64.PubMedPubMedCentralCrossRef
92.
Wagner LI, Gray RJ, Sparano JA, Whelan TJ, Garcia SF, Yanez B, et al. Patient-reported cognitive impairment among women with early breast cancer randomly assigned to endocrine therapy alone versus chemoendocrine therapy: results from TAILORx. J Clin Oncol. 2020;38(17):1875–86.PubMedPubMedCentralCrossRef
93.
Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol. 2001;19(14):3306–11.PubMedCrossRef
94.
McCloskey E. Effects of third-generation aromatase inhibitors on bone. Eur J Cancer. 2006;42(8):1044–51.PubMedCrossRef
95.
Saad F, Adachi JD, Brown JP, Canning LA, Gelmon KA, Josse RG, et al. Cancer treatment-induced bone loss in breast and prostate cancer. J Clin Oncol. 2008;26(33):5465–76.PubMedCrossRef
96.
Body JJ, Bergmann P, Boonen S, Boutsen Y, Devogelaer JP, Goemaere S, Reginster JY, Rozenberg S, Kaufman JM. Management of cancer treatment-induced bone loss in early breast and prostate cancer – a consensus paper of the Belgian Bone Club. Osteoporos Int. 2007;18(11):1439–50.PubMedCrossRef
97.
Shapiro CL, Van Poznak C, Lacchetti C, Kirshner J, Eastell R, Gagel R, et al. Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO Clinical Practice Guideline. J Clin Oncol. 2019;37(31):2916–46.PubMedCrossRef
98.
Coleman R, Hadji P, Body JJ, Santini D, Chow E, Terpos E, et al. Bone health in cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2020;31(12):1650–63.PubMedCrossRef
99.
Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kässmann H, Piswanger-Sölkner JC, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol. 2008;9(9):840–9.PubMedCrossRef
100.
Nuzzo F, Gallo C, Lastoria S, Di Maio M, Piccirillo MC, Gravina A, et al. Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study. Ann Oncol. 2012;23(8):2027–33.PubMedCrossRef
101.
Wilson C, Bell R, Hinsley S, Marshall H, Brown J, Cameron D, et al. Adjuvant zoledronic acid reduces fractures in breast cancer patients; an AZURE (BIG 01/04) study. Eur J Cancer. 2018;1990(94):70–8.CrossRef
102.
Gravina A, De Laurentiis M, et al. The HOBOE multicenter randomized phase 3 trial in premenopausal patients with hormone-receptor positive early breast cancer comparing triptorelin plus either tamoxifen or letrozole or zoledronic acid + letrozole—8yr efficacy analysis. Abstract Book of the 24th National Congress of Italian Association of Medical Oncology (AIOM). Tumori J. 108(4_suppl):1–194.
103.
Bober SL, Kingsberg SA, Faubion SS. Sexual function after cancer: paying the price of survivorship. Climacteric. 2019;22(6):558–64.PubMedCrossRef
104.
Advani P, Brewster AM, Baum GP, Schover LR. A pilot randomized trial to prevent sexual dysfunction in postmenopausal breast cancer survivors starting adjuvant aromatase inhibitor therapy. J Cancer Surviv Res Pract. 2017;11(4):477–85.CrossRef
105.
Loprinzi CL, Abu-Ghazaleh S, Sloan JA, vanHaelst-Pisani C, Hammer AM, Rowland KM, et al. Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer. J Clin Oncol. 1997;15(3):969–73.PubMedCrossRef
106.
Pagano T, De Rosa P, Vallone R, Schettini F, Arpino G, Giuliano M, et al. Fractional microablative CO2 laser in breast cancer survivors affected by iatrogenic vulvovaginal atrophy after failure of nonestrogenic local treatments: a retrospective study. Menopause. 2018;25(6):657–62.PubMedCrossRef
107.
Hummel SB, van Lankveld JJDM, Oldenburg HSA, Hahn DEE, Kieffer JM, Gerritsma MA, et al. Efficacy of internet-based cognitive behavioral therapy in improving sexual functioning of breast cancer survivors: results of a randomized controlled trial. J Clin Oncol. 2017;35(12):1328–40.PubMedCrossRef
108.
Bober SL, Fine E, Recklitis CJ. Sexual health and rehabilitation after ovarian suppression treatment (SHARE-OS): a clinical intervention for young breast cancer survivors. J Cancer Surviv. 2020;14(1):26–30.PubMedCrossRef
109.
Neuhouser ML, Aragaki AK, Prentice RL, Manson JE, Chlebowski R, Carty CL, et al. Overweight, obesity, and postmenopausal invasive breast cancer risk: a secondary analysis of the women’s health initiative randomized clinical trials. JAMA Oncol. 2015;1(5):611–21.PubMedPubMedCentralCrossRef
110.
Soldato D, Blondeaux E, Bruzzone M, Mura S, De Laurentiis M, Turletti A, et al. Dissecting the prognostic role of baseline body mass index (BMI) in early breast cancer (BC): individual patient-level analysis from five mammella interGruppo (MIG) and gruppo italiano mammella (GIM) randomized clinical trials (RCTs). J Clin Oncol. 2023;41(16_suppl):12067–12067.CrossRef
111.
Vernaci G, Dieci MV, Manfrin S, Mantiero M, Falci C, Faggioni G, et al. BMI is an independent prognostic factor for late outcome in patients diagnosed with early breast cancer: a landmark survival analysis. The Breast. 2019;47:77–84.PubMedCrossRef
112.
113.
Powell-Wiley TM, Poirier P, Burke LE, Després JP, Gordon-Larsen P, Lavie CJ, et al. Obesity and cardiovascular disease: a scientific statement from the American heart association. Circulation. 2021;143(21):e984–1010.PubMedPubMedCentralCrossRef
114.
McTiernan A. Weight, physical activity and breast cancer survival. Proc Nutr Soc. 2018;77(4):403–11.PubMedCrossRef
115.
Demark-Wahnefried W, Campbell KL, Hayes SC. Weight management and its role in breast cancer rehabilitation. Cancer. 2012;118(8 Suppl):2277–87.PubMedCrossRef
116.
Sinicrope FA, Dannenberg AJ. Obesity and breast cancer prognosis: weight of the evidence. J Clin Oncol. 2011;29(1):4–7.PubMedCrossRef
117.
Bellet M, Gray KP, Francis PA, Láng I, Ciruelos E, Lluch A, et al. Twelve-month estrogen levels in premenopausal women with hormone receptor-positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the Suppression of Ovarian Function Trial (SOFT): the SOFT-EST Substudy. J Clin Oncol. 2016;34(14):1584–93.PubMedPubMedCentralCrossRef
118.
Pfeiler G, Königsberg R, Fesl C, Mlineritsch B, Stoeger H, Singer CF, et al. Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. J Clin Oncol. 2011;29(19):2653–9.PubMedCrossRef
119.
Fansa S, Ghusn W, Tama E, Nicolalde B, Anazco D, D’Andre S, et al. FRI077 Efficacy of anti-obesity medications among breast cancer survivors taking aromatase inhibitors. J Endocr Soc. 2023;7(Supplement_1):bvad114.087.PubMedCentralCrossRef
120.
Harvie M, Pegington M, McMullan D, Bundred N, Livingstone K, Campbell A, et al. The effectiveness of home versus community-based weight control programmes initiated soon after breast cancer diagnosis: a randomised controlled trial. Br J Cancer. 2019;121(6):443–54.PubMedPubMedCentralCrossRef
Metadata
Title
Ovarian Suppression: Early Menopause and Late Effects
Authors
Chiara Molinelli, MD
Flavia Jacobs, MD
Guilherme Nader-Marta, MD
Roberto Borea, MD
Graziana Scavone, MSc
Silvia Ottonello, MSc
Piero Fregatti, MD, PhD
Cynthia Villarreal-Garza, MD, PhD
Jyoti Bajpai, MD
Hee Jeong Kim, MD, PhD
Silvia Puglisi, MD
Evandro de Azambuja, MD, PhD
Matteo Lambertini, MD, PhD
Publication date
13-03-2024
Publisher
Springer US
Published in
Current Treatment Options in Oncology / Issue 4/2024
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI
https://doi.org/10.1007/s11864-024-01190-8

Other articles of this Issue 4/2024

Current Treatment Options in Oncology 4/2024 Go to the issue

ReviewPaper

Who Should Receive Immunotherapy for Advanced Gastroesophageal Cancer?

ReviewPaper

Harnessing the Potential of Real-World Evidence in the Treatment of Colorectal Cancer: Where Do We Stand?

ReviewPaper

Pioneering the Way: The Revolutionary Potential of Antibody–Drug Conjugates in NSCLC

ReviewPaper

Treatment Options for Distal Rectal Cancer in the Era of Organ Preservation

ReviewPaper

Social Determinants of Health and the Link to Colorectal Cancer Outcomes

ReviewPaper

Role of ctDNA in gynecologic malignancies
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits